Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-07-01Clinical Trial Update: MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 trial of MGCD0103 in combination with azacitidine (Vidaza) for relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2015-06-26Clinical Trial Update: Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma [Phase 2]
A Phase 2 trial evaluating infusion of blood cells (lymphocytes) to stimulate the immune system for fighting leukemia/lymphoma was terminate…
-
CLINICAL_TRIALS trial_result · 2015-06-09Clinical Trial Update: An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma. [Phase 1]
Phase 1 trial of palbociclib (PD-0332991) in patients with mantle cell lymphoma has completed, with results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-06-04Clinical Trial Update: Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 trial of Zevalin (ibritumomab tiuxetan) and Velcade (bortezomib) for relapsed/refractory mantle cell lymphoma was terminated; result…
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease [Phase 2]
Phase 2 trial update reporting completion of a study evaluating interleukin-12 in patients with various previously treated non-Hodgkin lymph…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-04-13Clinical Trial Update: Study of Bortezomib in Combination With Cyclophosphamide and Rituximab [Phase 2]
Phase 2 study of bortezomib in combination with cyclophosphamide and rituximab in mantle cell lymphoma and other lymphomas has completed wit…
-
CLINICAL_TRIALS trial_result · 2015-03-13Clinical Trial Update: Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) [Phase 2]
Phase 2 clinical trial results showing safety and efficacy of PCI-32765 (ibrutinib) in relapsed/refractory mantle cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies [Phase 2]
A Phase 2 feasibility study evaluating a 60-minute rapid infusion rituximab protocol in patients with indolent or intermediate-grade B-cell …
-
CLINICAL_TRIALS trial_result · 2015-02-11Clinical Trial Update: A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies [Phase 1]
A Phase 1 pilot study evaluated co-infusing ex vivo expanded cord blood cells with an unmanipulated cord blood unit in patients undergoing c…
-
CLINICAL_TRIALS trial_result · 2015-01-27Clinical Trial Update: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating rituximab, cyclophosphamide, bortezomib, and dexamethasone in relapsed/refractory low-grade follicular lym…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms [Phase 1]
A Phase 1 trial evaluating the combination of bortezomib and flavopiridol in patients with recurrent or refractory indolent B-cell neoplasms…
-
CLINICAL_TRIALS trial_result · 2014-11-26Clinical Trial Update: A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. [Phase 2]
This update reports the results of a Phase 2 study of rituximab (MabThera) added to standard chemotherapy in patients with previously untrea…
-
CLINICAL_TRIALS trial_result · 2014-11-17Clinical Trial Update: Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 3]
Phase 3 trial evaluating Rituximab-containing regimens with either Velcade (bortezomib) or Vincristine in newly diagnosed mantle cell lympho…
-
CLINICAL_TRIALS trial_result · 2014-11-05Clinical Trial Update: Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating combination chemotherapy with or without bortezomib in relapsed or refractory mantle cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-10-30Clinical Trial Update: Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma [Phase 2]
This clinical trial update reports results from a Phase 2 study evaluating the combination of chemotherapy and rituximab in patients with un…
-
CLINICAL_TRIALS trial_result · 2014-10-22Clinical Trial Update: Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma [Phase 2]
This is a Phase 2 study of Bendamustine hydrochloride in combination with Rituximab in patients with relapsed or refractory mantle cell lymp…
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This ClinicalTrials.gov update reports a terminated phase 1/2 trial evaluating fenretinide with rituximab for B-cell non-Hodgkin lymphomas; …
-
CLINICAL_TRIALS trial_result · 2014-09-19Clinical Trial Update: Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) [Phase 1]
This update covers a completed Phase I study evaluating the combination of panobinostat and bortezomib in relapsed and/or refractory Mantle …
-
CLINICAL_TRIALS trial_result · 2014-09-11Clinical Trial Update: Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) [Phase 1, Phase 2]
Phase 1/2 safety and tolerability study of SNS01-T in relapsed or refractory B-cell malignancies sponsored by Senesco Technologies. The tria…
-
CLINICAL_TRIALS trial_result · 2014-09-05Clinical Trial Update: Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial results evaluating rituximab after autologous stem cell transplant in relapsed B-cell non-Hodgkin lymphoma have been completed…
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab [Phase 2]
A phase 2 trial evaluating lenalidomide plus rituximab in patients with CD5+/CD20+ hematologic malignancies who relapse after rituximab, inc…
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating agatolimod sodium in combination with rituximab and Yttrium-90 ibritumomab tiuxetan for adults with re…
-
CLINICAL_TRIALS trial_result · 2014-08-06Clinical Trial Update: Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial update evaluating the combination of iodine-131 tositumomab with fludarabine phosphate in older patients undergoing autologous…
-
CLINICAL_TRIALS trial_result · 2014-08-06Clinical Trial Update: Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial update describing treatment with genetically engineered lymphocytes, cyclophosphamide, and aldesleukin in relapsed or refracto…
-
CLINICAL_TRIALS trial_result · 2014-07-30Clinical Trial Update: Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of ofatumumab and bortezomib in adults with relapsed CD20-positive lymphomas, including diffuse lar…